- Conditions
- Crohn's Disease
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
- Interventions
- Vedolizumab
- Biological
- Lead sponsor
- Alimentiv Inc.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Charleston, South Carolina • Houston, Texas
- Conditions
- Colitis, Ulcerative, Crohn Disease
- Interventions
- Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Cypress, California • Miami, Florida
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more
- Conditions
- Crohn Disease
- Interventions
- certolizumab pegol (CDP870, CZP), Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 24
- States / cities
- Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more
- Conditions
- Crohn's Disease
- Interventions
- GSK1605786A
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 40
- States / cities
- Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 35 more
- Conditions
- Crohn Disease
- Interventions
- Ozanimod
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 190
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
- Conditions
- Crohn's Disease
- Interventions
- Risankizumab SC, Placebo for risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 79
- States / cities
- Sun City, Arizona • Corona, California • Coronado, California + 65 more
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab pegol, Azathioprine
- Biological · Drug
- Lead sponsor
- Gastroenterology Research of America
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- Zasocitinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Glen Burnie, Maryland • Tyler, Texas
- Conditions
- Crohn Disease
- Interventions
- Etrolizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 62
- States / cities
- Arcadia, California • La Jolla, California • Long Beach, California + 53 more
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- Risankizumab, Trosunilimab, ABBV-701
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 59
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 55 more
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
- Conditions
- Crohn's Disease
- Interventions
- GSK1605786A, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 48
- States / cities
- Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 43 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-78934804, Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 20
- States / cities
- Anaheim, California • Chula Vista, California • Los Alamitos, California + 17 more
- Conditions
- Crohn Disease
- Interventions
- VTX958, VTX958 Placebo
- Drug
- Lead sponsor
- Ventyx Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 26
- States / cities
- Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
- Conditions
- Crohn's Disease, IBD
- Interventions
- Brazikumab Induction Dose, Brazikumab Maintenance Dose
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Afimkibart
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo, BMS-936557 (Anti-IP-10 Antibody)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
- Conditions
- Crohn's Disease
- Interventions
- RHB-104, Placebo
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Anaheim, California • La Mirada, California + 37 more
- Conditions
- Crohn Disease
- Interventions
- Icotrokinra, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,092 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 61
- States / cities
- Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 49 more
- Conditions
- Crohn Disease
- Interventions
- Ozanimod, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 81
- States / cities
- Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more